Parnaparin, a low-molecular-weight heparin, prevents P-selectindependent formation of platelet-leukocyte aggregates in human whole blood

Norma Maugeri; Giovannina Di Fabio; Miriam Barbanti; Giovanni de Gaetano; Maria Benedetta Donati; Chiara Cerletti

doi:10.1160/TH06-12-0680

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2007; 97(06): 965-973
DOI: 10.1160/TH06-12-0680

Platelets and Blood Cells

Schattauer GmbH

Parnaparin, a low-molecular-weight heparin, prevents P-selectindependent formation of platelet-leukocyte aggregates in human whole blood

Norma Maugeri

¹Laboratory of Cell Biology and Pharmacology of Thrombosis, Research Laboratories, “John Paul II” Centre for High Technology Research and Education in Biomedical Sciences, Catholic University, Campobasso, Italy

,

Giovannina Di Fabio

¹Laboratory of Cell Biology and Pharmacology of Thrombosis, Research Laboratories, “John Paul II” Centre for High Technology Research and Education in Biomedical Sciences, Catholic University, Campobasso, Italy

,

Miriam Barbanti

²Alfa Wassermann, Bologna, Italy

,

Giovanni de Gaetano

¹Laboratory of Cell Biology and Pharmacology of Thrombosis, Research Laboratories, “John Paul II” Centre for High Technology Research and Education in Biomedical Sciences, Catholic University, Campobasso, Italy

,

Maria Benedetta Donati

¹Laboratory of Cell Biology and Pharmacology of Thrombosis, Research Laboratories, “John Paul II” Centre for High Technology Research and Education in Biomedical Sciences, Catholic University, Campobasso, Italy

,

Chiara Cerletti

¹Laboratory of Cell Biology and Pharmacology of Thrombosis, Research Laboratories, “John Paul II” Centre for High Technology Research and Education in Biomedical Sciences, Catholic University, Campobasso, Italy

› Author Affiliations

Abstract

Summary

Parnaparin, a low-molecular-weight heparin (LMWH), prevents platelet activation and interaction with polymorphonuclear leukocyte (PMN) in a washed cell system. The in-vitro effect of parnaparin was studied here on platelet-PMN aggregates formed with more physiologic approaches in whole blood, in parallel with unfractionated heparin and enoxaparin, another LMWH. Citrated blood from healthy subjects was stimulated: i) from passage through the “Platelet Function Analyzer” (PFA-100), a device that exposes blood to standardized high shear flow through collagen/ADP cartridges; ii) by collagen and ADP (2 and 50 µg/ml, respectively) added in combination under stirring in an aggregometer cuvette; iii) with recombinant Tissue Factor, to generate thrombin concentrations able to activate platelets without inducing blood clotting, or iv) the Thrombin Receptor Activating Peptide-6 (TRAP-6). Platelet P-selectin and platelet-PMN aggregates were measured by flow cytometry upon stimulation of blood. Fibrinogen binding to platelets and markers of PMN activation were also detected. Platelet P-selectin expression and platelet-PMN aggregate formation were induced in all four activation conditions tested. Parnaparin prevented in a concentration-dependent manner (0.3–0.8 IUaXa/ml) the expression of P-selectin and the formation of mixed aggregates, while the two reference heparin preparations had a much weaker effect. Platelet fibrinogen binding and PMN activation markers (fibrinogen binding, CD11b and CD40) were also prevented by parnaparin. These data extend in more physiological systems of platelet activation, the anti-inflammatory profile of parnaparin, previously reported in washed cells. The greater effect of parnaparin, as compared to the reference heparins, could be due to chemico-physical differences possibly unrelated to their anticoagulant effect.

Keywords

LMWH - inflammation - platelet-PMN aggregates - P-selectin

Full Text

References

References
1 Nelson RM, Cecconi O, Roberts WG. et al. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 1993; 82: 3253-3258.
2 Xie X, Rivier AS, Zakrzewicz A. et al. Inhibition of Selectin-mediated cell adhesion and prevention of acute inflammation by non anticoagulant sulphated saccharides. J Biol Chem 2000; 275: 34818-34825.
3 Wang L, Brown JR, Varki A. et al. Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J Clin Invest 2002; 110: 127-136.
4 Frampton JE, Faulds D. Parnaparin. A review of its pharmacology, and clinical application in the prevention and treatment of thromboembolic and other vascular disorders. Drugs 1994; 47: 652-676.
5 Dettori AG. Parnaparin: a review of its pharmacological profile and clinical application. Drugs Today 1995; 31: 19-35.
6 Maugeri N, de Gaetano G, Barbanti M. et al. Prevention of platelet-polymorphonuclear leukocyte interactions: new clues to the antithrombotic properties of parnaparin, a low molecular weight heparin. Haematologica 2005; 90: 833-839.
7 Hayward CP, Harrison P, Cattaneo M. et al. The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006; 4: 312-319.
8 Maugeri N, Donati MB, de Gaetano G. et al. Formation of mixed platelet-PMN leukocyte aggregates in the Platelet Function Analyzer (PFA-100) device. Thromb Haemost 2007; 97: 156-157.
9 Maugeri N, Santarelli MT, Lazzari MA. Circulating platelet/polymorphonuclear leukocyte mixed-cell aggregates in patients with mechanical heart valve replacement. Am J Hematol 2000; 65: 93-98.
10 Maugeri N, Giordano G, Petrilli MP. et al. Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug?. J Thromb Haemost 2006; 4: 2593-2598.
11 Evangelista V, Manarini S, Rotondo S. et al. Platelet/ polymorphonuclear leukocyte interaction in dynamic conditions: evidence of adhesion cascade and cross talk between P-selectin and the beta 2 integrin CD11b/CD18. Blood 1996; 88: 4183-4194.
12 Evangelista V, Manarini S, Sideri R. et al. Platelet/ polymorphonuclear leukocyte interaction: P-selectin triggers protein-tyrosine phosphorylation-dependent CD11b/CD18 adhesion: role of PSGL-1 as a signaling molecule. Blood 1999; 93: 876-885.
13 Vandendries ER, Furie BC, Furie B. Role of P-selectin and PSGL-1 in coagulation and thrombosis. Thromb Haemost 2004; 92: 1076-1085.
14 Cerletti C, Evangelista V, de Gaetano G. P-Selectinbeta2- integrin cross-talk: a molecular mechanism for polymorphonuclear leukocyte recruitment at the site of vascular damage. Thromb Haemost 1999; 82: 787-793.
15 Hu H, Varon D, Hjemdahl P. et al. Platelet-leukocyte aggregation under shear stress: differential involvement of selectins and integrins. Thromb Haemost 2003; 90: 679-687.
16 Martins PdA, Zwaginga JJ. Leukocyte-platelet aggregates: new particles reflecting and effecting cardiovascular disease. Thromb Haemost 2005; 94: 1120-1121.
17 Mickelson JK, Lakkis NM, Villarreal-Levy G. et al. Leukocyte activation with platelet adhesion after coronary angioplasty: a mechanism for recurrent disease?. J Am Coll Cardiol 1996; 28: 345-353.
18 Furman MI, Benoit SE, Barnard MR. et al. Increased platelet reactivity and circulating m platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol 1998; 31: 352-358.
19 Michelson AD, Barnard MR, Krueger LA. et al. Circulating monocyte–platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001; 104: 1533-1537.
20 Maugeri N, Kempfer AC, Evangelista V. et al. Enhanced response to chemotactic activation of polymorphonuclear leukocytes from patients with heart valve replacement. Thromb Haemost 1997; 77: 71-74.
21 Jensen MK, de Nully Brown P, Lund BV. et al. Increased circulating platelet-leukocyte aggregates myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count. Br Haematol 2000; 110: 116-124.
22 Tefferi A. The granulocyte connection in MPD-associated thrombosis. Blood 2007; 109: 2270-2271.
23 Koenig A, Norgard-Sumnicht K, Linhardt R. et al. Differential interactions of heparin and heparan sulfate glycosaminoglycan with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest 1998; 101: 877-889.
24 Theoret JF, Chahrour W, Yacoub D. et al. Recombinant P-selectin glycoprotein-ligand-1 delays thrombininduced platelet aggregation: a new role for P-selectin in early aggregation. Br J Pharmacol 2006; 148: 299-305.
25 Fritzsche J, Alban S, Ludwig RJ. et al. The influence of various structural parameters of semisynthetic sulfated polysaccharides on the P-selectin inhibitory capacity. Biochem Pharmacol 2006; 72: 474-485.
26 Wei M, Tai G, Gao Y. et al. Modified heparin inhibits P-selectin-mediated cell adhesion of human colon carcinoma cells to immobilized platelets under dynamic flow conditions. J Biol Chem 2004; 279: 29202-29210.
27 Ludwig RJ, Alban S, Bistrian R. et al. The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo. Thromb Haemost 2006; 95: 535-540.
28 Casu B, Guerrini M, Torri G. Structural and conformational aspects of the anticoagulant and antithrombotic activity of heparin and dermatan sulfate. Curr Pharm Des 2004; 10: 939-949.
29 Naggi A, Casu B, Perez M. et al. Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting. J Biol Chem 2005; 280: 12103-12113.
30 Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-1143.